Business Wire

CA-ARMIS

24.6.2024 17:16:26 CEST | Business Wire | Press release

Share
Armis Named ‘Outperformer’ and ‘Leader’ in GigaOm Radar Report for Operational Technology Security for Second Consecutive Year

Armis, the asset intelligence cybersecurity company, today announced that it has been named a Leader and Outperformer in the 2024 GigaOm Radar Report for Operational Technology (OT) Security. This is the second year running is recognized as a Leader in the field of OT Security, cementing its status as a mature platform solution providing proactive end-to-end security for cross-vertical organizations looking for a cohesive approach to OT Security management.

Armis scored multiple 5/5 perfect scores showcasing Armis’ customer-centric vision to deliver OT security built on deep asset context, proactive threat intelligence and total vulnerability management. From cost and ease of use to scalability and flexibility and certification, Armis was recognized for being built for smooth deployment in OT environments.

“The on-going development of the Armis Centrix™ platform has enabled us to offer complete end to end OT security management from complete visibility, vulnerability remediation and management through to advanced AI threat detection,” said Yevgeny Dibrov, CEO and Co-founder of Armis. “I am grateful to GigaOm for recognizing, not just our leadership position, but also awarding us 'Outperformer status', praising the developments we have made this past year.”

The GigaOm Radar is a thoroughly comprehensive technology analysis of OT security solutions on the market today, focusing on the latest innovation and critical capabilities that customers need to protect their entire environment. It also benchmarks current solutions and is able to effectively track how OT/ICS security has evolved in order to stay ahead of modern threat actors and attack vectors.

“Armis has excelled in rapidly advancing its technological offerings and has notably enhanced its threat detection capabilities over the past year, pushing the boundaries of innovation in OT security,” said Chris Ray, Research Analyst at GigaOm. “Armis is positioned as a Platform Play because it offers an extensive and integrated security platform capable of addressing multiple OT security concerns, making it well-suited for organizations seeking comprehensive solutions. It is classified as Innovative due to its aggressive approach in introducing new features and capabilities, which highlights its commitment to staying ahead in technology advancements. Armis has achieved Leader status thanks to its effective market penetration and the robustness of its security solutions.”

Within the GigaOm Radar for OT Security, Armis Centrix™ is recognized for:

  • Asset Discovery - Armis' automated asset discovery feature received a 5/5 score for surpassing traditional methods by incorporating passive network discovery, active asset querying techniques, integration-based approaches, and asset profiling. This thorough strategy ensures precise identification of all devices, managed or unmanaged, granting organizations a complete view of their network landscape.
  • Dynamic Network Segmentation - Additionally, Armis received a 5/5 score for its dynamic network segmentation, utilizing knowledge of VLANs, subnets, and wireless networks to create device segments as the dynamic attack surface requires, and provide insights into architectural changes for more secure environments.
  • Managing Complex, Converged Environments - Armis demonstrated proficiency in managing diverse environments, including the OT, IT, IoT, and medical sectors. Armis Centrix™ showcased strong adherence to industry standards and regulatory requirements, scoring a 5/5 for business certification criterion thus instilling trust and confidence in its customers. Notable certifications include FedRAMP, DoD Impact Level 4, ISO 27001, ISO 28018, and SOC 2 type 2.
  • Next-Generation AI Threat Detection - With the addition of actionable threat intelligence capabilities this year Armis displayed huge growth in AI technologies for threat detection. Scoring a 5/5, Armis was applauded for using AI to identify attacks still in the formulation stage as well as pinpointing anomalous behavior, unusual activities, malicious code, and other threats in real time. Armis integrates with SIEM, SOAR, XDR, and ASM solutions, ensuring comprehensive coverage and visibility across the entire attack surface.
  • Integration with IT security systems - Ensuring coordinated security efforts across both IT and OT environments. This convergence enhances the overall cybersecurity posture of an organization, addressing complex, multifaceted threats that span the IT-OT divide.
  • Providing visualization of OT asset relationships - Offering best-in-class dashboards and Purdue modeling to represent how OT assets connect and interact within an organization's network. This visibility is essential for understanding potential pathways of cyber threats and optimizing security responses.

“Armis offers a comprehensive suite of security features well-suited for SMBs, large enterprises, and public sector organizations,” continued Ray. “Leaders like Armis demonstrate robust platform capabilities with wide-reaching security features, making them stalwarts in the industry.”

The 2024 GigaOm Radar Report is a valuable resource for organizations aiming to enhance their OT security posture. It offers a thorough overview of the OT security market and highlights the leading vendors in the space. To learn more, read the Armis blog highlighting key findings from this year’s report here.

About Armis

Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240624790874/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye